United States · Exchanges & live quotes · Nasdaq

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

Published by Nasdaq · United States 28 min ago

Detailed summary

Key PointsJohnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies.

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading

Burnham Heads to COP31 Torn Between Cheaper Power and Net Zero

Hyperliquid (HYPE) Surges 3.2% on Korea Listings, Buybacks

Nvidia Stock Is Bouncing. Is a Broad Market Rally ‘Likely to Follow’ Its Rise?

Cboe Global Markets

Market Metrics That Matter: Derivatives October 2026 Volume Highlights

Trump vows to stand with Hegseth if he’s impeached

The open AI-native stack on Kubernetes: From open models to distributed inference and agents